Study design and data source
PsA, Drug retention, RA
Using data collected prospectively from five Phase III, randomized, placebo-controlled clinical trials, this post-hoc analysis evaluated drug retention of golimumab (either 50 mg or 100 mg administered subcutaneously every four weeks) for up to five years in participants with RA, PsA, and AS. Analyses of the five-year data from each of these individual studies have been reported previously [Drug retention data from four of the five studies (GO-BEFORE, GO-FORWARD, GO-REVEAL, and GO-RAISE) were pooled for analysis of 1Details of patient eligibility and study design were reported previously [